证券代码：301093 证券简称：华兰股份 江苏华兰药用新材料股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | |----------------------------------|----------------------------------|------------------------------------------------------|-------|------------------------------------------------------|-------| | | | | | | | | 投资者关系活动类别 ☐特定对象调研 | | ☐分析师会议 | | | | | | ☐ 媒体采访 | ☐ 业绩说明会 | | | | | | ☐ 新闻发布会 | ☐路演活动 | | | | | | 现场参观 | | | | | | | ☐ 其他（请文字说明其他活动内容） | | | | | | 形式 | 现场 ☐ 网上 | ☐ 电话会议 | | | | | 参与单位名称及人员姓名 | | | | ...

Group 1: Company Overview - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. is listed under stock code 301093 and abbreviated as Hualan Shares [1]. Group 2: Investor Relations Activities - The investor relations activity took place on October 26, 2022, from 14:00 to 16:00 in the company conference room [2]. - Participants included representatives from Taikang Asset and Xinda Securities [2]. Group 3: Production Challenges - The production of coated rubber stoppers is more complex than conventional stoppers, with lower yield rates due to multiple factors including mixing temperature, curing conditions, and contamination [2]. - Key production difficulties include compatibility of film materials, adhesion strength, effective coverage area, and damage rates during production [2]. Group 4: Market Insights - As of 2021, the COVID-19 vaccination coverage exceeded 85%, leading to a saturation in demand for COVID-related products, resulting in a reduced revenue contribution from new COVID orders in the first three quarters [3]. - The company holds a significant market share in the vaccine rubber stopper sector [3]. Group 5: Capacity Expansion - The company is currently constructing automated and intelligent factory projects, expected to be operational by June 30, 2023, and expanding pre-filled medical packaging capacity by September 30, 2023 [3]. - A new project aims to produce 6 billion new medical sealing elastomers annually, currently in the land acquisition phase [3]. Group 6: Financial Health - The company has a healthy accounts receivable situation, with approximately 70% of clients being reputable pharmaceutical companies, leading to good cash flow [3]. - Credit terms for clients range from 30 to 120 days based on their credit ratings [3]. Group 7: Risk Management - The company has minimal foreign exchange risk as its foreign currency income primarily comes from exports, which are used to purchase imported raw materials [3]. Group 8: Sales Strategy - The sales team is evaluated annually based on metrics such as invoiced revenue, profit, cash collection speed, and inventory levels, with targets distributed across teams and individuals [3]. Group 9: Future Market Trends - The joint review and approval system is expected to accelerate the reshaping of the rubber stopper industry, favoring companies with strong capabilities and quality products [4]. - Smaller, less technologically advanced companies are likely to be eliminated from the market, while leading firms will expand through acquisitions and new projects, increasing market concentration [4].

Financial Performance - The company's revenue for Q3 2022 was ¥139,016,329.90, a decrease of 43.13% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,505,728.26, down 73.28% year-on-year[4] - The basic earnings per share decreased by 79.95% to ¥0.1523[4] - Total operating revenue for the third quarter was CNY 407,250,718.10, a decrease of 36.6% compared to CNY 642,406,273.67 in the same period last year[23] - The net profit for the third quarter was 76,654,882.51 CNY, down 58.5% from 184,607,274.91 CNY year-over-year[24] - Basic and diluted earnings per share were both 0.569 CNY, compared to 1.828 CNY in the previous year[25] - The company reported a total operating income of 533,151,748.79 CNY, down from 616,211,339.50 CNY year-over-year[25] Cash Flow - The company reported a significant reduction in cash flow from operating activities, with a net cash flow of ¥68,235,480.89, down 36.24% year-to-date[4] - The net cash flow from operating activities decreased by 36.24% to ¥68,235,480.89 compared to the same period last year due to a reduction in sales revenue[12] - Cash flow from operating activities generated a net amount of 68,235,480.89 CNY, a decline of 36.3% from 107,020,587.92 CNY in the same period last year[25] - The net cash flow from investing activities saw a significant increase of 2049.54%, amounting to -¥1,692,203,069.54, attributed to cash management investments and participation in equity funds[12] - Cash flow from investing activities resulted in a net outflow of 1,692,203,069.54 CNY, compared to an outflow of 78,723,826.41 CNY in the previous year[26] - The net cash flow from financing activities decreased by 508.50% to -¥132,530,515.94, primarily due to profit distribution during the period[12] - The net increase in cash and cash equivalents dropped dramatically by 31822.95% to -¥1,756,872,945.47, reflecting a substantial decrease in net cash flow from investing and financing activities[12] - Cash and cash equivalents decreased by 1,756,872,945.47 CNY during the quarter, contrasting with an increase of 5,538,176.03 CNY in the same period last year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,526,098,594.25, a decrease of 4.06% from the end of the previous year[4] - The total assets as of September 30, 2022, were CNY 2,526,098,594.25, a slight decrease from CNY 2,632,955,496.82 at the beginning of the year[22] - Current assets totaled CNY 2,085,494,598.27, down 8.9% from CNY 2,289,422,795.88 at the start of the year[21] - Non-current assets increased to CNY 440,603,995.98, up 28.3% from CNY 343,532,700.94 at the beginning of the year[21] - Total liabilities decreased to CNY 127,266,985.24 from CNY 216,512,103.42, a reduction of 41.3%[22] - The company's equity attributable to shareholders was CNY 2,398,831,609.01, slightly down from CNY 2,416,443,393.40 at the beginning of the year[22] Investments and Expenses - The company experienced a 36.61% decline in total revenue year-to-date, primarily due to a substantial decrease in orders for vaccine rubber stoppers[11] - The company reported a 100% increase in investment income to ¥10,767,767.06 from cash management products[11] - The company’s other non-current financial assets increased by 100% to ¥25,500,000.00 due to investments in equity funds[9] - The company’s construction in progress increased by 151.00% to ¥85,465,239.55, reflecting ongoing projects[10] - The company’s financial expenses decreased significantly by 218.99% due to reduced bank loan interest expenses[11] - Research and development expenses were CNY 25,986,410.95, a decrease of 10.4% compared to CNY 29,153,591.30 in the previous year[23] - Cash paid for various taxes decreased by 53.24% to ¥41,832,235.26, reflecting reduced tax payments[13] - Cash received from investment recoveries was ¥810,000,000.00, marking a 100% increase due to cash management actions[13] - Cash paid for investment activities reached ¥2,422,500,000.00, representing a 100% increase as the company engaged in cash management and equity fund investments[13] - The company distributed dividends amounting to ¥92,147,725.94, a significant increase of 2254.60% compared to the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,592, with the top ten shareholders holding significant stakes, including Jiangyin Hualan Electromechanical Technology Co., Ltd. at 21.00%[14] Audit and Reporting - The company has not undergone an audit for the third quarter report[27] - The company’s total assets and liabilities were not disclosed in the provided documents, indicating a need for further financial details in future reports[24]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥268,234,388.20, a decrease of 32.60% compared to ¥397,981,328.81 in the same period last year[24]. - The net profit attributable to shareholders was ¥56,149,154.25, down 47.95% from ¥107,873,220.90 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥38,242,169.30, a decline of 64.44% compared to ¥107,537,357.27 in the previous year[24]. - The net cash flow from operating activities was ¥28,924,081.22, which is 25.46% lower than ¥38,805,437.14 in the same period last year[24]. - Basic earnings per share decreased by 60.75% to ¥0.42 from ¥1.07 in the previous year[24]. - The total profit amounted to 65.8 million yuan, down 49.30% year-on-year, while the net profit attributable to shareholders was 56.1 million yuan, a decline of 47.95%[43]. - The decline in performance was primarily due to a substantial decrease in domestic COVID-19 vaccine orders and reduced daily medical services due to the pandemic[43]. - The company's gross profit margin for the pharmaceutical manufacturing sector was 44.67%, down 14.74% from the previous year, reflecting a 32.58% decline in revenue[61]. Market and Industry Position - The company operates in the pharmaceutical packaging materials sector, specifically focusing on the research, production, and sales of pharmaceutical rubber stoppers, which are essential for various types of injectable drugs and vaccines[32]. - The market for pharmaceutical rubber stoppers is expected to grow due to factors such as economic growth, increasing per capita income, and an aging population, despite a significant drop in orders during the reporting period due to decreased COVID-19 vaccine demand[33]. - The company has a market share exceeding 10% in the overall pharmaceutical rubber stopper market, with a leading position in the membrane rubber stopper segment[41]. - The company employs a direct sales model primarily targeting domestic pharmaceutical companies, while also utilizing a buyout distribution model for international markets[40]. - The company has seen a significant increase in its customer base, now covering approximately 70% of the top 100 pharmaceutical companies in China[41]. Research and Development - Research and development expenses amounted to ¥17,449,241.51, a decrease of 8.21% from ¥19,010,560.84 in the previous year[58]. - The company focuses on continuous innovation in product technology and has developed a complete coating technology process for its products[45]. - The company has allocated 50 million yuan for R&D in innovative materials for the upcoming fiscal year[116]. - The company has allocated 100 million yuan for R&D in new technologies over the next two years[120]. Strategic Initiatives - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[116]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[116]. - A strategic partnership with a leading healthcare provider is expected to boost sales by 30% in the next two years[116]. - The company plans to invest in automation and intelligent factory upgrades, as well as expand the production capacity of pre-filled medical packaging materials, using funds raised from its IPO[92]. Corporate Governance and Compliance - The company emphasizes strict compliance with laws and regulations to protect the rights of shareholders and creditors, enhancing corporate governance and operational standards[106]. - The company held a shareholders' meeting during the reporting period, ensuring shareholders' rights to information and participation, while maintaining a robust financial position without any related party fund occupation[107]. - The company has committed to avoiding competition with its controlling shareholders and has issued a letter of commitment to ensure no development, production, or sale of competing products as of the date of the commitment[129]. Cash Flow and Financial Position - The company's cash and cash equivalents saw a net decrease of ¥1,766,074,200.74, primarily due to substantial reductions in cash flows from investing and financing activities[58]. - The total assets at the end of the reporting period were ¥2,505,499,497.71, a decrease of 4.84% from ¥2,632,955,496.82 at the end of the previous year[24]. - The company's total current assets as of June 30, 2022, amounted to CNY 2,131,632,932.83, a decrease from CNY 2,289,422,795.88 at the beginning of the year, reflecting a decline of approximately 6.9%[173]. - The company's accounts receivable slightly decreased from CNY 159,837,212.07 to CNY 155,548,431.84, a decline of approximately 2.3%[173]. Social Responsibility - The company emphasizes its commitment to social responsibility, maintaining compliance and communication with stakeholders while promoting technological research and product innovation[105]. - In the first half of 2022, the company donated a total of 358,900.24 yuan to support social welfare initiatives[111].

Financial Performance - The company's revenue for Q1 2022 was ¥130,918,431.95, a decrease of 22.16% compared to ¥168,185,663.92 in the same period last year[3] - Net profit attributable to shareholders was ¥31,165,938.51, down 24.22% from ¥41,125,705.42 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥22,220,408.33, reflecting a significant decline of 45.40% compared to ¥40,695,309.18 in the previous year[3] - Basic and diluted earnings per share were both ¥0.231, a decrease of 43.24% from ¥0.407 in the previous year[3] - The operating profit for Q1 2022 was CNY 36,844,806.34, down from CNY 49,956,751.65 in the same period last year, reflecting a decline of 26.2%[24] - The company reported a basic and diluted earnings per share of CNY 0.231 for Q1 2022, down from CNY 0.407 in Q1 2021, representing a decrease of 43.3%[25] Cash Flow and Assets - The net cash flow from operating activities increased by 840.96%, reaching ¥23,119,604.44, compared to a negative cash flow of -¥3,120,228.75 in the same period last year[3] - The total current assets amounted to CNY 2.28 billion, slightly down from CNY 2.29 billion at the beginning of the year[20] - The total liabilities were CNY 185.43 million, a decrease from CNY 216.51 million at the beginning of the year[21] - The company’s total assets stood at CNY 2.63 billion, showing a slight increase from CNY 2.63 billion at the beginning of the year[21] - The total cash and cash equivalents at the end of Q1 2022 were CNY 155,194,793.33, a decrease from CNY 1,860,005,090.28 at the beginning of the period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,640[11] - Jiangyin Hualan Electromechanical Technology Co., Ltd. holds 21.00% of shares, totaling 28,280,000 shares[12] - Huaxia Life Insurance Co., Ltd. owns 16.30% of shares, amounting to 21,956,522 shares[12] - The top ten shareholders collectively hold significant stakes, with the largest shareholder holding over 21%[12] - The total number of restricted shares at the end of the period is 103,125,403 shares[16] - The company plans to release 27,500 restricted shares on a specified date[16] - The company has a total of 18,054,262 shares under lock-up until November 1, 2022[16] - The company has no preferred shareholders as of the reporting period[14] - The company has a clear strategy for shareholder management, with specific release dates for restricted shares[15] - The company maintains a diverse shareholder base, including both institutional and individual investors[12] Investment and Strategy - The company reported a significant increase in cash management products, with trading financial assets rising to ¥1,518,485,188.89, a 100% increase[7] - The company received a tax refund of ¥1,830,806.52, marking a 100% increase compared to the previous year[10] - Investment cash outflow for cash management products was ¥1,812,000,000.00, indicating a significant investment strategy shift[10] - The company plans to continue its long-term strategies, focusing on automation and intelligent factory transformation projects[17] - The company aims to expand the production capacity of pre-filled medical packaging materials and enhance its technological reserves[17] Research and Development - Research and development expenses for the period were CNY 9.24 million, up from CNY 7.19 million in the previous year[23] Operating Expenses - The total operating expenses for Q1 2022 were CNY 136,948,208.16, compared to CNY 145,808,895.39 in Q1 2021, indicating a reduction of 6.1%[27] Other Financial Metrics - The cash flow from investing activities showed a net outflow of CNY -1,727,470,246.32, compared to CNY -12,273,086.57 in the same period last year[28] - The company reported a significant decrease in cash and cash equivalents, with a balance of CNY 175.10 million compared to CNY 1.87 billion at the beginning of the year[19] - The company did not conduct any audited financial reporting for Q1 2022[29]

Dividend Distribution - The company plans to distribute a cash dividend of 7 RMB per 10 shares to all shareholders, based on a total of 134,666,667 shares[4]. - The cash dividend represents 100% of the total profit distribution amount, with a distributable profit of 331,146,621.61 CNY[181]. - The average cash dividend per 10 shares is 7.00 CNY, totaling 94,266,666.90 CNY distributed to shareholders[181]. Financial Performance - The report includes a comprehensive overview of the company's financial indicators and performance metrics for the year 2021[17]. - The company's operating revenue for 2021 was approximately ¥820.87 million, representing an increase of 83.92% compared to ¥446.32 million in 2020[23]. - The net profit attributable to shareholders for 2021 was approximately ¥216.02 million, a significant increase of 165.52% from ¥81.36 million in 2020[23]. - The net cash flow from operating activities for 2021 was approximately ¥216.54 million, up 62.32% from ¥133.40 million in 2020[23]. - The total assets at the end of 2021 reached approximately ¥2.63 billion, a 323.56% increase from ¥621.62 million at the end of 2020[23]. - The company maintained a basic earnings per share of ¥2.026 for 2021, which is a 151.36% increase from ¥0.806 in 2020[23]. - The company's gross margin for the reporting period was 55.12%, an increase of 8.25% compared to the previous year's gross margin of 46.87%[73]. - The revenue for the year 2021 was approximately ¥820.87 million, representing an 83.92% increase from ¥446.32 million in 2020[80]. - The sales volume of pharmaceutical packaging products increased by 63.73% year-on-year, primarily due to a significant rise in orders for film-coated stoppers and COVID-19 vaccine stoppers[85]. Market Position and Growth - The company is recognized as a leading enterprise in the pharmaceutical packaging materials sector, particularly in the rubber stopper market[33]. - The market for pharmaceutical rubber stoppers is expected to continue growing due to factors such as economic growth, increasing income levels, and an aging population[32]. - The company has established partnerships with over 240 new clients, including major domestic pharmaceutical companies, covering more than 60% of the top 100 pharmaceutical enterprises in China[37]. - The company holds over 10% market share in the pharmaceutical rubber stopper industry in China, with its core product, film-coated stoppers, ranking among the top in the industry[49]. - The company is positioned as a key partner in the domestic COVID-19 vaccine supply chain, contributing to capacity building and supply assurance[61]. - The company anticipates that the competitive landscape will shift, with smaller firms being eliminated, allowing leading companies to capture more market share[117]. Research and Development - The company has been involved in the research and development of film-coated stoppers for nearly 20 years, holding multiple national invention and utility model patents[35]. - Research and development investment reached ¥42.08 million, a 77.82% increase from ¥23.66 million in the previous year[75]. - The company is focusing on the development of high-quality, high-standard vaccine stoppers compatible with COVID-19 vaccines, aiming to ensure vaccine safety and effectiveness[95]. - The company is advancing the development of a new generation of self-destructing, non-metallic sealing elastomer components, targeting higher safety in pharmaceutical applications[95]. - The company aims to achieve zero defects in production through automation and advanced detection systems, improving product quality and reducing economic losses[96]. - The company is developing a low-metal ion leaching catheter flushing piston to enhance the safety of flushing liquid medications[96]. Risk Management - The report includes a section on potential risks that the company may face in its future development, which investors are advised to review carefully[4]. - The company faces risks related to the procurement of key raw materials, with a significant reliance on suppliers from countries like the US, Japan, and Canada, which could impact cost control and profitability if there are major changes in the supply chain[128]. - The centralized procurement policy may exert cost pressures on pharmaceutical companies, potentially impacting the company's performance if reliant on a few major clients[40]. Corporate Governance - The company has a complete governance structure with no overlap in management roles with controlling shareholders[147]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards and effective oversight of company operations[135]. - The company has established a transparent performance evaluation system for senior management, adhering to legal and regulatory standards for appointments[139]. - The company has implemented measures to ensure the independence of its operations from its controlling shareholder, maintaining separate financial and operational structures[143]. - The company has a dedicated information disclosure management system to ensure compliance with regulatory requirements and provide equal access to information for all shareholders[141]. Employee Management - The total number of employees at the end of the reporting period is 861, with 616 in the parent company and 245 in major subsidiaries[178]. - The employee composition includes 622 production personnel, 51 sales personnel, 104 technical personnel, 13 financial personnel, and 71 administrative personnel[178]. - The training program includes professional skills, leadership training, and management skills, aimed at enhancing employee capabilities[180]. - The company has established a performance-oriented corporate culture to align business goals with employee performance management[179]. Social Responsibility - The company contributed a total of 1,093,882 yuan to various charitable causes in 2021[195]. - The company actively participated in social welfare activities, including donations for disaster relief and educational support[196]. - The company is committed to green development and has implemented energy-saving technologies and practices[194]. Financial Health - The company has maintained a solid financial position with no related party fund occupation or external guarantee issues[193]. - The company has no retired employees requiring pension expenses, indicating a focus on current workforce management[178]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[192].